FFA
SYRE icon

Farther Finance Advisors’s Spyre Therapeutics SYRE Stock Holding History

Farther Finance Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100K Buy
1,129
+1,055
+1,426% +$77K ﹤0.01% 2702
2026
Q1 		$3.62K Buy
74
+37
+100% +$1.4K ﹤0.01% 4658
2025
Q4 		$1.21K Buy
37
+27
+270% +$706 ﹤0.01% 4864
2025
Q3 		$168 Buy
+10
New +$163 ﹤0.01% 4756

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Farther Finance Advisors's SYRE Position: Q2 2026 in Review

Farther Finance Advisors increased its Spyre Therapeutics (SYRE) stake by 1,426% in Q2 2026, buying an estimated $77K and bringing the position to 1,129 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2702.

Farther Finance Advisors first reported a position in SYRE in Q3 2025 and has held it in 4 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Farther Finance Advisors held 1,129 shares of Spyre Therapeutics worth $100K as of Q2 2026.
  • Farther Finance Advisors bought 1,055 Spyre Therapeutics shares in Q2 2026, an estimated $77K.
  • Spyre Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #2702 holding.
  • Farther Finance Advisors first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.